<![CDATA[Accutar Biotechnology, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=39530>Wed, 29 Apr 2026 20:15:05 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024]]>https://www.newswire.co.kr/newsRead.php?no=990827Sun, 02 Jun 2024 15:30:00 +0900<![CDATA[아큐타 바이오테크놀로지, ASCO 2024에서 ER+/HER2- 유방암 환자를 대상으로 한 AC699 단독요법의 제1상 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=990829Sun, 02 Jun 2024 15:30:00 +0900<![CDATA[Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer]]>https://www.newswire.co.kr/newsRead.php?no=937222Mon, 27 Dec 2021 11:40:00 +0900<![CDATA[아큐타 바이오테크놀로지, 전립선 치료 신약 AC0176의 임상 1상 신청 FDA 승인]]>https://www.newswire.co.kr/newsRead.php?no=937223Mon, 27 Dec 2021 11:40:00 +0900